Bryan N. Patenaude

Dr. Bryan N. Patenaude

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2015 in Neurology
Verified
Journal Article
Closed access
PDF file
HMHannah C. McLane
Hannah C. McLane
ABAaron L. Berkowitz
Aaron L. Berkowitz
BPBryan N. Patenaude
Bryan N. Patenaude
EMErica D. McKenzie
Erica D. McKenzie
EWEmma Wolper
Emma Wolper
FMFarrah J. Mateen
Farrah J. Mateen
Objective: To determine the availability, accessibility, and affordability of EEG, EMG, CSF analysis, head CT, and brain MRI for neurologic disorders across countries. Methods: An online, 60-question survey was distributed to neurology practitioners in 2014 to assess the presence, wait time, and cost of each test in private and public health sectors. Data were stratified by World Bank country income group. Affordability was calculated with reference to the World Health Organization9s definition of catastrophic health expenditure as health-related out-of-pocket expenditure of >40% of disposable household income, and assessment of providers9 perceptions of affordability to the patient. Results: Availability of EEG and EMG is correlated with higher World Bank income group (correlation coefficient 0.38, test for trend p = 0.046; 0.376, p = 0.043); CSF, CT, and MRI did not show statistically significant associations with income groups. Patients in public systems wait longer for neurodiagnostic tests, especially MRI, EEG, and urgent CT (p < 0.0001). The mean cost per test, across all tests, was lower in the public vs private sector (US $55.25 vs $214.62, p < 0.001). Each drop in World Bank income group is associated with a 29% decrease in the estimated share of the population who can afford a given test (95% confidence interval −33.4, 25.2; p < 0.001). In most low-income countries surveyed, only the top 10% or 20% of the population was able to afford tests below catastrophic levels. In surveyed lower-middle-income countries, >40% of the population, on average, could not afford neurodiagnostic tests. Conclusions: Neurodiagnostic tests are least affordable in the lowest income settings. Closing this “diagnostic gap” for countries with the lowest incomes is essential.

1 December 2016 in Epilepsy & Behavior
Verified
Journal Article
Closed access
ASAltaf Saadi
Altaf Saadi
BPBryan N. Patenaude
Bryan N. Patenaude
FMFarrah J. Mateen
Farrah J. Mateen


1 December 2018 in Food Policy
Verified
Journal Article
Open access
JCJennifer Coates
Jennifer Coates
BPBryan N. Patenaude
Bryan N. Patenaude
BRBeatrice Lorge Rogers
Beatrice Lorge Rogers
ARAlemzewed Challa Roba
Alemzewed Challa Roba
YWYitbarek Kidane Woldetensay
Yitbarek Kidane Woldetensay
KSKathryn L. Spielman
Kathryn L. Spielman

1 August 2019 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
KHKathryn Holroyd
Kathryn Holroyd
AVAndre Vogel
Andre Vogel
KLKat Lynch
Kat Lynch
BGBrittany Gazdag
Brittany Gazdag
MVMatthew Voghel
Matthew Voghel
FMFarrah J. Mateen
Farrah J. Mateen

4 August 2020 in PharmacoEconomics
Verified
Journal Article
Open access
PDF file
Gatien de BrouckerGatien de Broucker
Gatien de Broucker
SSSo Yoon Sim
So Yoon Sim
LBLogan Brenzel
Logan Brenzel
MGMargaret Gross
Margaret Gross
BPBryan N. Patenaude
Bryan N. Patenaude
DCDagna Constenla
Dagna Constenla
Background: Cost-of-illness data from empirical studies provide insights into the use of healthcare resources including both expenditures and the opportunity cost related to receiving treatment. Objective: The objective of this systematic review was to gather cost data and relevant parameters for hepatitis B, pneumonia, meningitis, encephalitis caused by Japanese encephalitis, rubella, yellow fever, measles, influenza, and acute gastroenteritis in children in low- and middle-income countries. Data Sources: Peer-reviewed studies published in public health, medical, and economic journals indexed in PubMed (MEDLINE), Embase, and EconLit. Study Eligibility Criteria, Participants, and Interventions: Studies must (1) be peer reviewed, (2) be published in 2000–2016, (3) provide cost data for one of the nine diseases in children aged under 5 years in low- and middle-income countries, and (4) generated from primary data collection. Limitations: We cannot exclude missing a few articles in our review. Measures were taken to reduce this risk. Several articles published since 2016 are omitted from the systematic review results, these articles are included in the discussion. Conclusions and Implications of Key Findings: The review yielded 37 articles and 267 sets of cost estimates. We found no cost-of-illness studies with cost estimates for hepatitis B, measles, rubella, or yellow fever from primary data. Most estimates were from countries in Gavi preparatory (28%) and accelerated (28%) transition, followed by those who are initiating self-financing (22%) and those not eligible for Gavi support (19%). Thirteen articles compared household expenses to manage illnesses with income and two articles with other household expenses, such as food, clothing, and rent. An episode of illness represented 1–75% of the household’s monthly income or 10–83% of its monthly expenses. Articles that presented both household and government perspectives showed that most often governments incurred greater costs than households, including non-medical and indirect costs, across countries of all income statuses, with a few notable exceptions. Although limited for low- and middle-income country settings, cost estimates generated from primary data collection provided a ‘real-world’ estimate of the economic burden of vaccine-preventable diseases. Additional information on whether common situations preventing the application of official clinical guidelines (such as medication stock-outs) occurred would help reveal deficiencies in the health system. Improving the availability of cost-of-illness evidence can inform the public policy agenda about healthcare priorities and can help to operationalize the healthcare budget in local health systems to respond adequately to the burden of illness in the community.